Luspatercept
Inrebic (fedratinib) is a prescription medication used to treat adults with intermediate-2 or high-risk primary myelofibrosis or secondary myelofibrosis related to polycythemia vera or essential thrombocythemia. It belongs to a class of drugs called Janus kinase (JAK) inhibitors that work by reducing the overactive JAK signaling associated with this blood cancer. This oral therapy is typically prescribed when other treatments have not been effective or have stopped working.
Inrebic is an oral JAK inhibitor used to treat adults with certain types of myelofibrosis, a rare blood cancer.
Key facts at a glance
- RxNorm
- 2197496
- Generic
- Inrebic
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Inrebic is indicated for the treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (also known as chronic idiopathic myelofibrosis) and for the treatment of adult patients with intermediate-2 or high-risk secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia).
Inrebic is a Janus kinase 2 (JAK2) inhibitor. It works by blocking the activity of JAK2, a protein that is often mutated and overactive in myelofibrosis. By inhibiting this overactive signaling pathway, the medication helps reduce the abnormal blood cell production and symptoms associated with the disease, such as an enlarged spleen and constitutional symptoms.
Inrebic carries a boxed warning for serious and fatal cases of Wernicke's encephalopathy, a neurological emergency caused by thiamine deficiency. Patients should have thiamine levels monitored before and during treatment. Other common side effects include diarrhea, nausea, vomiting, and anemia. The medication may cause serious liver problems and should be used with caution in patients with renal or hepatic impairment. Inrebic is typically taken once daily with or without food and should not be used in patients with severe renal impairment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy